Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab injection for intraocular neovascularization in children
jRCTs051180175Completed
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab in Intraocular neovascularization (IONV) and retinopathy of prematurity (ROP). Primary endpoint: Incidence of retinal detachment after treatment. Started Aug 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
Intraocular neovascularization (IONV)retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on jRCTs051180175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180175.